Jamey Paul Weichert

This inventor holds 45 USPTO granted patents and 18 published patent applications, plus 5 CIPO patents and 9 EPO patents, primarily in Cancer Imaging. Top assignees: Wisconsin Alumni Research Foundation, Cellectar, Inc., University of Michigan. Active years: 1989-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jamey Paul Weichert. Retrieved from https://idiyas.com/inventor/jamey-paul-weichert

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 45 (Patent Applications = 18)

% Patents Active = 97.8

CIPO Patents = 5 (Patent Applications = 2)

EPO Patents = 9 (Patent Applications = 9)

Average Co-Inventor Count = 4.0

ph-index = 11

Forward Citations = 298(Granted Patents)

Location History:

Ann Arbor, MI (US) (1989 - 2009)
Fitchburg, WI (US) (2001 - 2022)
Madison, WI (US) (2022)
Sun Prairie, WI (US) (2019 - 2023)

Company Filing History:

14 out of 4,249

Wisconsin Alumni Research Foundation

University of Michigan

patents

4. 8 out of 10

Cellectar Biosciences, Inc.

patents

5. 1 out of 8

The Board of Regents Acting for and on Behalf of the University of

patents

Years Active: 1989-2026

Loading Chart...

Areas of Expertise:

Tumor Targeting

Gadolinium Agents

Phospholipid Ether

Cancer Imaging

Radiotherapy Chelates

Pediatric Tumors

Cancer Treatment

Immune Modulation

Circulating Tumor Cells

Therapeutic Agents

Fluorescent Compounds

Radiohalogenated Agents

45 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12564635 - Long-lived gadolinium based tumor targeted imaging and therapy agents (2026-03-03),

2. 12491202 - Phospholipid ether analogs for imaging and targeted treatment of pediatric solid tumors (2025-12-09),

3. 12109256 - Radiohalogenated agents for in situ immune modulated cancer vaccination (2024-10-08),

4. 11730834 - Targeted radiotherapy chelates for in situ immune modulated cancer vaccination (2023-08-22),

5. 11633506 - Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies (2023-04-25),

6. 11623007 - Long-lived gadolinium based tumor targeted imaging and therapy agents (2023-04-11),

7. 11467159 - Luminescent phospholipid analogs for the identification and isolation of circulating tumor cells (2022-10-11),

8. 11439709 - Phospholipid ether analogs as cancer-targeting drug vehicles (2022-09-13),

9. 11186598 - Radioactive phospholipid metal chelates for cancer imaging and therapy (2021-11-30),

10. 11147823 - Phospholipid ether analogs for imaging and targeted treatment of pediatric solid tumors (2021-10-19),

11. 10813998 - Long-lived gadolinium based tumor targeting imaging and therapy agents (2020-10-27),

12. 10751430 - Targeted radiotherapy chelates for in situ immune modulated cancer vaccination (2020-08-25),

13. 10736949 - Radiohalogenated agents for in situ immune modulated cancer vaccination (2020-08-11),

14. 10265398 - Long-lived gadolinium based tumor targeted imaging and therapy agents (2019-04-23),

15. 10007961 - Treatment planning system for radiopharmaceuticals (2018-06-26),

Title: Innovations of Jamey Paul Weichert in Cancer Treatment

Introduction

Jamey Paul Weichert, a prominent inventor based in Fitchburg, Wisconsin, has significantly contributed to the field of cancer treatment through his extensive research and numerous patents. With a remarkable portfolio of 43 patents, Weichert is recognized for his innovative approaches to immunotherapy and targeted radiotherapy.

Latest Patents

Among Weichert's latest patents are his groundbreaking inventions focused on improving cancer vaccination methods. One notable patent is centered on "Radiohalogenated agents for in situ immune modulated cancer vaccination." This method involves administering a radiohalogenated compound that targets malignant solid tumors and enhances the immune system's response by injecting a composition capable of stimulating specific immune cells in the tumor microenvironment.

Another significant invention is "Targeted radiotherapy chelates for in situ immune modulated cancer vaccination." This method utilizes a radioactive phospholipid metal chelate compound that is selectively retained in malignant solid tumors. By introducing agents that stimulate immune cells directly within the tumors, this approach represents a promising advancement in the field of cancer therapy.

Career Highlights

Weichert's career includes key positions at the Wisconsin Alumni Research Foundation and Cellectar, Inc., where he has been instrumental in the development of cutting-edge approaches to cancer treatment. His innovative methods have contributed to the evolution of therapeutic strategies in oncology, further solidifying his reputation as a leader in medical research.

Collaborations

Throughout his career, Weichert has collaborated with esteemed colleagues such as Anatoly Pinchuk and Marc Longino. These partnerships have fostered an environment of shared knowledge and innovation, leading to the continuous development of new solutions for cancer treatment.

Conclusion

Jamey Paul Weichert's impressive contributions to the field of cancer immunotherapy and targeted radiotherapy underscore his dedication to advancing medical technology. His innovative patents not only enhance the understanding of cancer treatment but also provide hope for improved patient outcomes in the fight against malignant tumors.

Profile summary based on public USPTO records.